{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"IDEAYA Biosciences, Inc."},"Symbol":{"label":"Symbol","value":"IDYA"},"Address":{"label":"Address","value":"7000 SHORELINE COURT,SUITE 350, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 443-6209"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations."},"CompanyUrl":{"label":"Company Url","value":"https://www.ideayabio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Darrin M. Beaupre","title":"Chief Medical Officer"},{"name":"Michael Anthony White","title":"Chief Scientific Officer"},{"name":"Paul A. Barsanti","title":"Chief Technology Officer"},{"name":"Yujiro S. Hata","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}